Genflow Signs CDAs with Animal Health Companies
Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has signed two Confidential Disclosure Agreements (CDAs) with leading animal health companies. The agreements facilitate data exchange and discussions for potential collaborations leveraging Genflow's proprietary SIRT6-centenarian gene therapy platform in the companion animal market.
The company's ongoing GF-1004 Dog Aging study with beagles has reported no adverse events to date. These partnerships could accelerate Genflow's path to commercialization by providing access to global scale, regulatory expertise, and commercial infrastructure, potentially leading to licensing agreements in the animal health sector.
Genflow Biosciences (OTCQB:GENFF), l'unica azienda europea quotata pubblicamente nel campo della longevità, ha firmato due Accordi di Riservatezza Confidenziali (CDAs) con importanti aziende nel settore della salute animale. Gli accordi facilitano lo scambio di dati e le discussioni per potenziali collaborazioni che sfruttano la piattaforma proprietaria di geneoterapia centenaria SIRT6 nel mercato degli animali da compagnia.
L'ongoing Studio GF-1004 Dog Aging sui beagle non ha registrato eventi avversi fino ad ora. Queste collaborazioni potrebbero accelerare il percorso di commercializzazione di Genflow fornendo accesso a scala globale, competenze regolatorie e infrastrutture commerciali, potenzialmente portando a contratti di licenza nel settore della salute animale.
Genflow Biosciences (OTCQB:GENFF), la única empresa europea que cotiza en bolsa en el ámbito de la longevidad, ha firmado dos Acuerdos de Confidencialidad (CDAs) con importantes compañías de salud animal. Los acuerdos facilitan el intercambio de datos y las conversaciones para posibles colaboraciones que aprovechen la plataforma propietaria de terapia génica centenaria SIRT6 en el mercado de mascotas.
El estudio en curso GF-1004 Dog Aging con dachshunds no ha reportado efectos adversos hasta la fecha. Estas asociaciones podrían acelerar el camino de Genflow hacia la comercialización al proporcionar acceso a escala global, experiencia regulatoria e infraestructura comercial, lo que podría traducirse en acuerdos de licencia en el sector de la salud animal.
Genflow Biosciences (OTCQB:GENFF), 유럽에서 유일하게 공개 상장된 장수 기업으로, 선도적인 반려동물 건강 기업들과 두 건의 비밀유지계약(CDA)을 체결했습니다. 이 계약들은 데이터 교환과 논의를 촉진하여 반려동물 시장에서 SIRT6-장수 유전자 치료 플랫폼을 활용한 잠재적 협력을 가능하게 합니다.
또한 회사의 진행 중인 GF-1004 개 실험(개 노화 연구)은 현재까지 부작용이 보고되지 않았습니다. 이러한 파트너십은 글로벌 규모 접근성, 규제 전문성, 상업 인프라를 제공하여 Genflow의 상업화 경로를 가속화하고, 동물 건강 분야에서 라이선스 계약으로 이어질 가능성을 열어줄 수 있습니다.
Genflow Biosciences (OTCQB:GENFF), la seule entreprise européenne cotée publiquement dans le domaine de la longévité, a signé deux accords de confidentialité (CDAs) avec des entreprises majeures du secteur de la santé animale. Les accords facilitent l'échange de données et les discussions pour d'éventuelles collaborations tirant parti de la plateforme propriétaire de thérapie génétique centenaire SIRT6 dans le marché des animaux de compagnie.
L'étude en cours GF-1004 Dog Aging chez les beagles n'a jusqu'à présent enregistré aucun effet indésirable. Ces partenariats pourraient accélérer le chemin de Genflow vers la commercialisation en offrant un accès à une échelle mondiale, une expertise réglementaire et une infrastructure commerciale, ce qui pourrait mener à des accords de licence dans le secteur de la santé animale.
Genflow Biosciences (OTCQB:GENFF), Europas einzige börsennotierte Longevity-Unternehmen, hat zwei Vertraulichkeitsvereinbarungen (CDAs) mit führenden Unternehmen im Tiergesundheitsbereich unterzeichnet. Die Abkommen erleichtern den Datenaustausch und Diskussionen für mögliche Kooperationen, die Genflows proprietäre SIRT6-Gen-Therapie-Plattform im Markt für Haustiere nutzen.
Die laufende GF-1004 Dog Aging-Studie mit Beagles hat bisher keine unerwünschten Zwischenfälle gemeldet. Diese Partnerschaften könnten Genflows Weg zur Kommerzialisierung beschleunigen, indem sie Zugang zu globaler Reichweite, regulatorischer Expertise und kommerzieller Infrastruktur bieten, was potenziell zu Lizenzvereinbarungen im Tiergesundheitssektor führen könnte.
Genflow Biosciences (OTCQB:GENFF)، الشركة الأوروبية الوحيدة المدرجة علنًا في مجال طول العمر، قد وقَّعت اتّفاقيتين لإفشاء المعلومات السرّية (CDAs) مع شركات رائدة في قطاع صحة الحيوان. تسهّل هذه الاتفاقيات تبادل البيانات والمناقشات لإمكانات التعاون التي تستفيد من منصة العلاج الجيني SIRT6-جيناه السنوية في سوق الحيوانات المصاحبة.
الدراسة المستمرة GF-1004 Dog Aging للكلاب من فصيلة البيغل لم تبلغ حتى الآن عن أية حوادث سلبية. هذه الشراكات يمكن أن تسرع مسار Genflow نحو الترخيص من خلال توفير الوصول إلى النطاق العالمي، والخبرة التنظيمية، والبنية التحتية التجارية، ما قد يؤدي إلى اتفاقيات ترخيص في قطاع صحة الحيوانات.
Genflow Biosciences (OTCQB:GENFF)，欧洲唯一公开上市的长寿领域公司，已与领先的动物健康公司签署了两份保密协议（CDA）。这些协议促进数据共享与讨论，推动在伴侣动物市场中利用Genflow的<SIRT6-百岁基因治疗平台的潜在合作。
该公司正在进行的GF-1004 狗衰老研究对杂交犬的试验迄今未报告不良事件。这些伙伴关系可能通过提供全球规模、监管专业知识和商业基础设施，来加速Genflow的商业化路径，可能在动物健康领域促成许可协议。
- None.
- Early-stage discussions with no guaranteed outcomes
- No immediate revenue impact from the CDAs
Genflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform
LONDON, UK / ACCESS Newswire / September 15, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has signed two Confidential Disclosure Agreements (CDAs) with leading animal health companies to facilitate the exchange of data and initiate discussions on potential collaborations.
These CDAs mark an important milestone in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. Building on the Company's ongoing GF-1004 Dog Aging (beagle) study which has reported no adverse events to date. The agreements will provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving quality of life in companion animals, a rapidly growing and high-value market segment.
Strategic Rationale
Genflow's first-in-class science, when combined with the resources of a large pharmaceutical partner, offers a faster path to commercialization therefore, derisking execution and maximizing shareholder value. Through such collaborations, Genflow can also unlock global scale, regulatory expertise, and commercial infrastructure more quickly accelerating both revenue generation and market penetration.
Dr. Eric Leire, CEO of Genflow, commented: "The signing of these CDAs reflects strong industry interest in our longevity platform and represents a further step toward building strategic partnerships in animal health. As we continue to advance GF-1004 in our canine trial, engaging with major animal health players will strengthen our pathway to potential licensing agreements and future commercialization."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Corporate Brokers | |
Capital Plus Partners Ltd | |
Jon Critchley, +44 207 432 0501 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What partnerships did Genflow Biosciences (GENFF) announce in September 2025?
What is the current status of Genflow's GF-1004 Dog Aging study?
How will the CDAs benefit Genflow Biosciences' business strategy?
What market is Genflow targeting with these animal health partnerships?
What is unique about Genflow's position in the European market?
